Marvel Biosciences (TSXV:MRVL) Debt-to-Equity : -0.61 (As of Jan. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Marvel Biosciences Debt-to-Equity?

Marvel Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$0.00 Mil. Marvel Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$1.50 Mil. Marvel Biosciences's Total Stockholders Equity for the quarter that ended in Jan. 2024 was C$-2.45 Mil. Marvel Biosciences's debt to equity for the quarter that ended in Jan. 2024 was -0.61.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Marvel Biosciences's Debt-to-Equity or its related term are showing as below:

TSXV:MRVL' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.61 Med: -0.6 Max: -0.45
Current: -0.61

During the past 4 years, the highest Debt-to-Equity Ratio of Marvel Biosciences was -0.45. The lowest was -1.61. And the median was -0.60.

TSXV:MRVL's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.145 vs TSXV:MRVL: -0.61

Marvel Biosciences Debt-to-Equity Historical Data

The historical data trend for Marvel Biosciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marvel Biosciences Debt-to-Equity Chart

Marvel Biosciences Annual Data

Trend

Jul20

Jul21

Jul22

Jul23

Debt-to-Equity

-0.58

Marvel Biosciences Quarterly Data
	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Debt-to-Equity	Get a 7-Day Free Trial										-	-1.61	-0.58	-0.45	-0.61

Competitive Comparison of Marvel Biosciences's Debt-to-Equity

For the Biotechnology subindustry, Marvel Biosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Marvel Biosciences's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marvel Biosciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Marvel Biosciences's Debt-to-Equity falls into.

Marvel Biosciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Marvel Biosciences's Debt to Equity Ratio for the fiscal year that ended in Jul. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	1)	/	-1.72
	=	-0.58

Marvel Biosciences's Debt to Equity Ratio for the quarter that ended in Jan. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	1.5)	/	-2.454
	=	-0.61

Marvel Biosciences (TSXV:MRVL) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Marvel Biosciences Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Marvel Biosciences's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Marvel Biosciences (TSXV:MRVL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marvel Biosciences Corp (TSXV:MRVL) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

MBCOF:USA

Address

505 - 8th Avenue SW, Suite 420, Calgary, AB, CAN, T2P1G2

Website

https://www.marvelbiotechnology.com

Marvel Biosciences Corp is a life sciences company focused on the discovery and development of a synthetic derivative compound of a known drug. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.

Executives

Joseph Roderick Matheson

Director, Senior Officer